LEADER 05323nam 22006614a 450 001 9910455887803321 005 20200520144314.0 010 $a1-280-27258-9 010 $a9786610272587 010 $a0-470-87053-2 035 $a(CKB)111087027105914 035 $a(EBL)219737 035 $a(OCoLC)54776196 035 $a(SSID)ssj0000163566 035 $a(PQKBManifestationID)11924447 035 $a(PQKBTitleCode)TC0000163566 035 $a(PQKBWorkID)10117536 035 $a(PQKB)11123345 035 $a(MiAaPQ)EBC219737 035 $a(Au-PeEL)EBL219737 035 $a(CaPaEBR)ebr10114001 035 $a(CaONFJC)MIL27258 035 $a(EXLCZ)99111087027105914 100 $a20030924d2004 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aGlobal securitisation and CDOs$b[electronic resource] /$fJohn Deacon 210 $aChichester, England ;$aHoboken, NJ $cWiley$d2004 215 $a1 online resource (690 p.) 225 1 $aWiley finance series 300 $aDescription based upon print version of record. 311 $a0-470-86987-9 320 $aIncludes bibliographical references (p. [657]-658) and index. 327 $aGlobal Securitisation and CDOs; Contents; Preface; About the Author; 1 Introduction; 1.1 Forms of securitisation; 1.2 Rationale for securitisation; 1.3 Global ABS markets; 2 Rating and Credit Structure; 2.1 Rating agencies; 2.2 Credit enhancement and liquidity; 2.3 Hedging and prepayment risk; 3 Deal Structure; 3.1 Ring-fencing and true sale; 3.2 SPVs and trusts; 3.3 Offshore centres; 3.4 Commonly used offshore jurisdictions; 3.5 Bonds and CP funding; 3.6 Securities laws; 3.7 US securities laws; 3.8 UK securities laws; 3.9 EU securities laws; 3.10 Tax treatment; 3.11 Accounting treatment 327 $a3.12 Capital treatment 3.13 Data and consumer regulation; 3.14 Regulatory approvals; 3.15 Administration and systems; 4 Investor Concerns; 4.1 Investor credit analysis; 4.2 Eligibility criteria; 4.3 Cash flow waterfall; 4.4 Bond pricing and valuation; 4.5 Performance and reporting; 5 Asset Classes; 5.1 ABS: Commercial and EETCs; 5.2 ABS: Consumer and credit cards; 5.3 Collateralised debt obligations; 5.4 Commercial mortgage-backed securities; 5.5 Covered bonds and Pfandbriefe; 5.6 Future flows; 5.7 Non-performing loans; 5.8 Real estate investment trusts; 5.9 Repackagings 327 $a5.10 Residential mortgage-backed securities 5.11 Trade receivables; 5.12 Whole business securitisation; 6 Opportunities and Challenges; 6.1 Introduction; 6.2 Significance of accounting and capital off-balance-sheet reform; 6.3 New Basel Accord; 7 Synthetics and Credit Derivatives; 7.1 Synthetic securitisation: Credit derivatives; 7.2 Super-senior pieces; 7.3 Pros and cons of synthetic securitisations for investors; 7.4 Terminology and types of credit derivative; 7.5 Use and pricing for credit derivatives; 7.6 Structure and concerns; 7.7 Regulatory capital advantages of synthetics 327 $a7.8 International capital treatment for credit derivatives 8 Whole Business Securitisation; 8.1 Benefits and requirements of whole business deals; 8.2 Structures; 8.3 Corporate valuation; 8.4 Rating analysis; 8.5 Feasibility in different countries; 8.6 Threats to whole business technology; 9 The European Union; 9.1 Ring-fencing and true sale; 9.2 Securities laws; 9.3 Tax treatment; 9.4 Accounting treatment; 9.5 Capital treatment; 9.6 Data protection/confidentiality; 9.7 Consumer protection; 9.8 Other issues; 10 Accounting for Securitisation; 10.1 US accounting standards 327 $a10.2 UK accounting standards 10.3 International Accounting Standards; 10.4 The influence of the European Union; 11 Capital; 11.1 Banking book; 11.2 Trading book; 11.3 New Basel Accord; 11.4 Basel capital arbitrage; 11.5 Off-balance-sheet treatment under Basel; 11.6 Basel capital treatment and new Basel proposals; 11.7 Capital for banking book exposures; 11.8 Capital for trading book exposures; 12 Global Securitisation Markets; 12.1 Argentina; 12.2 Australia; 12.3 Austria; 12.4 Belgium; 12.5 Bolivia; 12.6 Brazil; 12.7 Canada; 12.8 Chile; 12.9 China; 12.10 Colombia; 12.11 Czech Republic 327 $a12.12 Denmark 330 $a""This is an essential book for any practitioner, researcher or student of securitisation - concise and accurate coverage of the key aspects of securitisation on all the main and secondary markets of the world.""?Alexander Batchvarov, Managing Director, International Structured Product Strategy, Merrill Lynch, London. ""John Deacon's original book became the leading textbook for those genuinely interested in gaining a profound and detailed understanding of the arcane world of securitisation. The new, updated version confirms John's status as the top writer in this sector. Securitisation 410 0$aWiley finance series. 606 $aAsset-backed financing 606 $aDebt 608 $aElectronic books. 615 0$aAsset-backed financing. 615 0$aDebt. 676 $a658.15/26 700 $aDeacon$b John$f1969-$0885999 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910455887803321 996 $aGlobal securitisation and CDOs$91978251 997 $aUNINA LEADER 03752nam 2200649 450 001 9910460120603321 005 20200520144314.0 010 $a0-231-53877-4 024 7 $a10.7312/piot16626 035 $a(CKB)3710000000373555 035 $a(EBL)1885357 035 $a(SSID)ssj0001437468 035 $a(PQKBManifestationID)12540776 035 $a(PQKBTitleCode)TC0001437468 035 $a(PQKBWorkID)11364153 035 $a(PQKB)11733085 035 $a(StDuBDS)EDZ0001133097 035 $a(MiAaPQ)EBC1885357 035 $a(DE-B1597)458466 035 $a(OCoLC)979904334 035 $a(DE-B1597)9780231538770 035 $a(Au-PeEL)EBL1885357 035 $a(CaPaEBR)ebr11048458 035 $a(CaONFJC)MIL751460 035 $a(OCoLC)905307031 035 $a(EXLCZ)993710000000373555 100 $a20140707h20152015 uy| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAIDS between science and politics /$fPeter Piot ; translated by Laurence Garey 210 1$aNew York :$cColumbia University Press,$d[2015] 210 4$dİ2015 215 $a1 online resource (215 p.) 300 $aDescription based upon print version of record. 311 $a1-336-20174-6 311 $a0-231-16626-5 320 $aIncludes bibliographical references and index. 327 $aA heterogeneous and still evolving epidemic -- Hyperendemic HIV in Southern Africa : the heritage of apartheid -- AIDS as an international political issue -- A new type of transnational civil society movement -- The right to treatment -- Combination prevention -- The economics of AIDS -- Prominence of human rights -- The long-term view. 330 $aPeter Piot, founding executive director of the Joint United Nations Programme on HIV/AIDS (UNAIDS), recounts his experience as a clinician, scientist, and activist fighting the disease from its earliest manifestation to today. The AIDS pandemic was not only catastrophic to the health of millions worldwide but also fractured international relations, global access to new technologies, and public health policies in nations across the globe. As he struggled to get ahead of the disease, Piot found science does little good when it operates independently of politics and economics, and politics is worthless if it rejects scientific evidence and respect for human rights.Piot describes how the epidemic altered global attitudes toward sexuality, the character of the doctor-patient relationship, the influence of civil society in international relations, and traditional partisan divides. AIDS thrust health into national and international politics where, he argues, it rightly belongs. The global reaction to AIDS over the past decade is the positive result of this partnership, showing what can be achieved when science, politics, and policy converge on the ground. Yet it remains a fragile achievement, and Piot warns against complacency and the consequences of reduced investments. He refuses to accept a world in which high levels of HIV infection are the norm. Instead, he explains how to continue to reduce the incidence of the disease to minute levels through both prevention and treatment, until a vaccine is discovered. 606 $aAIDS (Disease)$xPrevention 606 $aCommunicable diseases 608 $aElectronic books. 615 0$aAIDS (Disease)$xPrevention. 615 0$aCommunicable diseases. 676 $a362.19697/92 700 $aPiot$b Peter$f1949-$0802327 702 $aGarey$b Laurence 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910460120603321 996 $aAIDS between science and politics$92485949 997 $aUNINA